Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.66 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.66 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094761 | 1.00 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6813023 | 0.93 | MAPK1 (0.57) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6817261 | 0.91 | MAPK1 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6817260 | 0.91 | MAPK1 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6095615 | 0.90 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6095607 | 0.90 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6817151 | 0.90 | MAPK1 (0.61) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6817149 | 0.90 | MAPK1 (0.61) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6816809 | 0.90 | MAPK1 (0.53) | MAPK14MAPK13MAPK12MAPK11MAPK1 | |
| SCHEMBL6813206 | 0.90 | MAPK1 (0.55) | MAPK14MAPK13MAPK12MAPK11MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100347151-C | Novel aminobenzophenones | LEO PHARMA AS (DK) | 2007-11-07 | — | — | CN | disclosed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| CN-1561327-A | Novel aminobenzophenones | LEO PHARMA AS (DK) | 2005-01-05 | — | — | CN | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | MAPK14 1972/4885MAPK13 2918/4885MAPK12 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.